StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a report published on Saturday. The firm issued a sell rating on the biotechnology company’s stock.
Aptevo Therapeutics Stock Up 7.0 %
Shares of APVO opened at $0.40 on Friday. The firm’s 50 day moving average price is $0.49 and its 200 day moving average price is $2.57. Aptevo Therapeutics has a twelve month low of $0.28 and a twelve month high of $22.44.
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.93) by $0.26. As a group, equities analysts forecast that Aptevo Therapeutics will post -8.86 earnings per share for the current fiscal year.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Further Reading
- Five stocks we like better than Aptevo Therapeutics
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- How to Invest in Silver: A Beginner’s Guide
- Why is the Ex-Dividend Date Significant to Investors?
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- What is the Dow Jones Industrial Average (DJIA)?
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
